Journal profile · INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
Journal of Infection and Chemotherapy
ISSN 1341-321X · eISSN 1437-7780 · Springer Japan · JAPAN · Bimonthly · Founded 1995
Journal of Infection and Chemotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.67; hybrid open access; APC about USD 2,650; median 91 days to acceptance (112 articles, last 24 months); acceptance rate 21% (journal website); 279 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Infection and Chemotherapy is published by Springer Japan and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pneumonia and Respiratory Infections, Antibiotic Resistance in Bacteria and Antimicrobial Resistance in Staphylococcus, together about 25.3% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Infection and Chemotherapy (JIC) - official journal of the Japanese Society of Chemotherapy, The Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control - welcomes original papers, review papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.
From the journal's Aims & Scope
Research area (LetPub): INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
Editor-in-chief Koichi Izumikawa NagasakiPublisher website
Editorial board by country: none in mainland China; most named Japan 74 (74 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pneumonia and Respiratory InfectionsMedicine8.9%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology8.8%
- Antimicrobial Resistance in StaphylococcusMedicine7.7%
- Antibiotics Pharmacokinetics and EfficacyMedicine6.8%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology5.9%
- Streptococcal Infections and TreatmentsMedicine5.2%
- Antifungal resistance and susceptibilityMedicine4.7%
- Respiratory viral infections researchMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.67LetPub ·
- Impact factor (publisher)
- 1.7Publisher website ·
- CiteScore 2026-06
- 3.1LetPub ·
- CiteScore (publisher)
- 3.1Publisher website ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.66LetPub ·
- h-index
- 53LetPub ·
- h-index
- 86OpenAlex ·
- i10-index
- 1,974OpenAlex ·
- 2-year mean citedness
- 1.71OpenAlex ·
- Self-citation rate
- 5.9%LetPub ·
- Share of gold OA articles
- 11.06%LetPub ·
Volume
- Articles per year
- 420LetPub ·
Articles by year OpenAlex count · 4,617 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 183 | 41 | 38 |
| 2025 | 279 | 99 | 423 |
| 2024 | 277 | 125 | 806 |
| 2023 | 255 | 139 | 1,259 |
| 2022 | 289 | 181 | 2,336 |
| 2021 | 297 | 163 | 3,173 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
91 daysMedian, submission to acceptance · P25–P75 67 days – 115 days
- Acceptance to online
- median 2 days (112 articles)
- Submission to online
- median 94 days
- Sample
- 112 articles with submission and acceptance dates (658 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- First decision after review
- 32 daysPublisher website ·
- Submission to acceptance
- 88 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,650 / EUR 2,480 / GBP 2,120 / JPY 328,680 | — | — | |
| Publisher website | USD 3,000 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9, with length limits
- case reportOriginal articleOriginal articles should be concise. Papers giving minimum inhibitory concentration (MIC) values of drugs without supporting clinical observatio…Length not stated
- committee reportCommittee reports from any organization concerned with medical practice or research in the fields of infection and chemotherapy will be considered for publicati…Length not stated
- editorialEditorials are considered for publication by invitation.Length not stated
- guidelineGuidelines for medical practice, clinical examinations, or experiments in the fields of infection and chemotherapy will be considered for publication. Abstract …Length not stated
- letterOriginal articleOriginal articles should be concise. Papers giving minimum inhibitory concentration (MIC) values of drugs without supporting clinical observatio…Length not stated
- letter to the editorQuestions or comments concerning recently published papers should be sent to the Editor, who will refer them to the authors. The questions and authors' replies …Length not stated
- noteNotes should be concise reports. The length of the text is less than 1800 words excluding Abstract, Acknowledgement and COI description. Tables and/or figures s…Length not stated
- reviewOriginal articleOriginal articles should be concise. Papers giving minimum inhibitory concentration (MIC) values of drugs without supporting clinical observatio…Length not stated
- review articlethan 250 words. Keywords are required. Review article The length of the text is from 2500 to 5000 words excluding Acknowledgement and COI description. Abstract …main text ≤ 5,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
Keywords: Immediately after the abstract, provide 3-6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of", etc.). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywor Model summary
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Source ↗Publisher website ·- Conflicts of interest Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
Source ↗Publisher website ·- Data availability
Formatting of funding sources: List funding sources in this standard way to facilitate compliance to funder's requirements:Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the U Model summary
List funding sources in this standard way to facilitate compliance to funder's requirements:Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Authors will be asked to transfer copyright of their articles to the Japanese S…
Source ↗Publisher website ·- Open access Open access
Open access: For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles is determined by the author's choice of user license. Model summary
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Japan
- Country or region
- JAPAN
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1995
- ISSN
- 1341-321X
- Electronic ISSN
- 1437-7780
- Society / sponsor
- Japanese Society of Chemotherapy
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Infection and Chemotherapy
What CAS zone is Journal of Infection and Chemotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Infection and Chemotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Infection and Chemotherapy?
The latest impact factor listed by LetPub is 1.67; CiteScore 3.1, h-index 86.
How long does peer review take at Journal of Infection and Chemotherapy?
Based on the dates recorded on 112 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 67–115 days); authors report an average review time of 3–8 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Infection and Chemotherapy based?
Of the 74 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Japan (74). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Infection and Chemotherapy?
According to LetPub and DOAJ records, Journal of Infection and Chemotherapy is indexed in SCIE and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Journal of Infection and Chemotherapy open access, and what is the APC?
Journal of Infection and Chemotherapy is a hybrid journal. For open-access publication: APC about USD 2,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .